Selective PPARα Modulator "K-808" (Pemafibrate) Granted "Breakthrough Therapy" Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis
RegulatorypositiveK-808Positive
AI Analysis
Summary
Kowa Company received FDA Breakthrough Therapy designation for K-808 (Pemafibrate), a selective PPARα modulator, as a treatment for primary biliary cholangitis on June 11, 2026. This designation accelerates the development and review process for the drug.
Outcome Details
Breakthrough Therapy designation granted
Importance:8/10
Sentiment:
0.85
Breakthrough TherapyFDA DesignationPPARα ModulatorRare DiseasePrimary Biliary Cholangitis
Read the original article
Published by PR Newswire Clinical Trials on June 30, 2026 2:00 PM